Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 31 04:00PM ET
6.35
Dollar change
+0.11
Percentage change
1.76
%
Index- P/E- EPS (ttm)-0.24 Insider Own44.95% Shs Outstand128.42M Perf Week20.49%
Market Cap50.56M Forward P/E- EPS next Y-3.53 Insider Trans2.49% Shs Float4.38M Perf Month29.86%
Income-30.46M PEG- EPS next Q-1.33 Inst Own4.56% Short Float2.63% Perf Quarter46.65%
Sales0.44M P/S114.90 EPS this Y51.93% Inst Trans2.60% Short Ratio0.86 Perf Half Y-27.30%
Book/sh-0.00 P/B- EPS next Y21.80% ROA-56.31% Short Interest0.12M Perf Year-18.59%
Cash/sh2.72 P/C2.33 EPS next 5Y- ROE-289.66% 52W Range3.82 - 12.00 Perf YTD7.05%
Dividend Est.- P/FCF- EPS past 5Y-18.22% ROI-275.89% 52W High-47.08% Beta0.46
Dividend TTM- Quick Ratio0.99 Sales past 5Y50.93% Gross Margin-324.21% 52W Low66.31% ATR (14)0.48
Dividend Ex-Date- Current Ratio0.99 EPS Y/Y TTM62.60% Oper. Margin-8166.29% RSI (14)62.36 Volatility8.08% 8.98%
Employees85 Debt/Eq- Sales Y/Y TTM-43.62% Profit Margin-6890.50% Recom1.00 Target Price53.86
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q81.93% Payout- Rel Volume0.31 Prev Close6.24
Sales Surprise-24.17% EPS Surprise29.72% Sales Q/Q-66.17% EarningsAug 07 BMO Avg Volume133.79K Price6.35
SMA2012.47% SMA5015.57% SMA200-7.86% Trades Volume41,212 Change1.76%
Date Action Analyst Rating Change Price Target Change
Oct-04-22Downgrade Oppenheimer Outperform → Perform
Jul-18-22Initiated H.C. Wainwright Buy $16
May-02-22Initiated Canaccord Genuity Buy $10
Sep-28-21Initiated Oppenheimer Outperform $20
Oct-25-24 12:09PM
Oct-21-24 01:13PM
Oct-11-24 02:55PM
Oct-09-24 01:31PM
08:00AM
10:46AM Loading…
Oct-03-24 10:46AM
Oct-02-24 07:21AM
Oct-01-24 04:00PM
Sep-30-24 08:30AM
Sep-26-24 11:44AM
Sep-16-24 08:30AM
Sep-04-24 11:27AM
Sep-03-24 10:38AM
08:00AM
Aug-29-24 12:13PM
10:17AM Loading…
Aug-23-24 10:17AM
Aug-13-24 12:47PM
Aug-12-24 08:00AM
Aug-09-24 09:00AM
Aug-08-24 08:00AM
Aug-07-24 08:23AM
Aug-06-24 08:00AM
Aug-05-24 08:00AM
Jul-17-24 07:00AM
Jul-16-24 07:00AM
Jul-12-24 10:34AM
Jul-11-24 09:00AM
Jul-09-24 08:00AM
Jun-24-24 08:00AM
Jun-21-24 07:09AM
07:37AM Loading…
Jun-18-24 07:37AM
07:00AM
Jun-12-24 07:46AM
07:00AM
Jun-11-24 07:00AM
Jun-05-24 08:00AM
May-28-24 07:30AM
May-14-24 08:00AM
May-10-24 07:30AM
May-08-24 12:54PM
08:55AM
08:00AM
06:00AM
May-01-24 08:30AM
Apr-16-24 04:01PM
Mar-19-24 08:30AM
Mar-15-24 08:00AM
Mar-13-24 09:30AM
08:00AM
Mar-07-24 08:00AM
Feb-29-24 08:00AM
Feb-22-24 08:00AM
Feb-05-24 02:30PM
Jan-24-24 08:30AM
Jan-10-24 09:00AM
Jan-08-24 07:00AM
Jan-03-24 04:25PM
Dec-22-23 03:00PM
Dec-21-23 07:46AM
07:00AM
07:00AM
Dec-19-23 09:00AM
Dec-15-23 03:00PM
Dec-14-23 08:36AM
Dec-12-23 08:30AM
Dec-08-23 02:19PM
Nov-23-23 09:00AM
Nov-14-23 08:30AM
Nov-09-23 09:00AM
Nov-07-23 08:57AM
08:00AM
Oct-31-23 08:30AM
Oct-26-23 08:30AM
Oct-19-23 08:30AM
Oct-17-23 08:30AM
Oct-11-23 09:00AM
Oct-06-23 02:15PM
Oct-05-23 10:00AM
Sep-29-23 03:00PM
08:30AM
Sep-28-23 08:00AM
Sep-27-23 09:00AM
Sep-25-23 04:00PM
07:00AM
Aug-30-23 08:20AM
Aug-29-23 07:00AM
Aug-14-23 08:00AM
Aug-02-23 07:00AM
Jun-28-23 11:19AM
07:13AM
Jun-26-23 08:00AM
Jun-21-23 09:20AM
07:20AM
Jun-16-23 08:00AM
Jun-15-23 04:38PM
04:29PM
07:00AM
May-25-23 08:00AM
May-12-23 04:00PM
Apr-25-23 04:05PM
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MATLIN DAVID JDirectorSep 30 '24Buy4.7592,307438,458444,491Oct 02 12:58 PM
Mortenson MarkChief Science OfficerSep 30 '24Buy4.7520,51297,43228,949Oct 01 04:17 PM
Etherington Robert DeeChief Executive OfficerSep 30 '24Buy4.7510,00047,50040,149Oct 01 04:17 PM
Etherington Robert DeeChief Executive OfficerJul 29 '24Option Exercise3.0027,32081,96030,149Jul 30 09:03 AM
General Resonance LLC10% OwnerApr 30 '24Sale0.4213,0005,41615,326,712May 08 12:16 PM
General Resonance LLC10% OwnerMay 01 '24Sale0.4013,0005,14815,313,712May 08 12:16 PM
General Resonance LLC10% OwnerApr 24 '24Sale0.3310,0003,27815,349,712May 01 05:13 PM
General Resonance LLC10% OwnerApr 09 '24Sale0.3922,5008,67415,428,212Apr 16 09:38 AM
MATLIN DAVID JDirectorNov 10 '23Buy0.41250,002102,5017,043,686Nov 13 07:48 AM